Nisotirostide record · updated 18h ago
Nisotirostide, also known as LY3457263, is a novel peptide that acts as a selective agonist for the neuropeptide Y2 (NPY2) receptor. This receptor is involved in various physiological processes, including appetite regulation and energy homeostasis. By activating the NPY2 receptor, nisotirostide is hypothesized to influence metabolic pathways that can lead to weight loss and improved glycemic control, making it a potential therapeutic option for conditions such as type 2 diabetes and obesity.
How it works: NPY2 receptor agonist
Development stage
where Nisotirostide sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.
Mass and formula from PubChem CID 171921325. No verified residue count for this compound.
| Study | Type | Year | Summary depth |
|---|---|---|---|
| Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept. FindingNisotirostide reduced mean body weight by 0.75 kg versus placebo (ns); when added to dulaglutide, up to 2.58 kg reduction was observed versus dulaglutide alone (p<0.05). | review | 2026 | Full text read0.80 |
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Nisotirostide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.